Pulmonx Co. (NASDAQ:LUNG) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Pulmonx Co. (NASDAQ:LUNG) has been given a consensus recommendation of “Moderate Buy” by the six brokerages that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $14.67.

Several equities analysts recently issued reports on the company. Wells Fargo & Company lowered their price target on Pulmonx from $14.00 to $10.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 1st. Stifel Nicolaus lowered their price objective on Pulmonx from $17.00 to $16.00 and set a “buy” rating on the stock in a research report on Thursday, October 31st. Finally, Canaccord Genuity Group raised their target price on Pulmonx from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Thursday, August 1st.

Insider Buying and Selling at Pulmonx

In other news, insider Geoffrey Beran Rose sold 4,586 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $6.70, for a total value of $30,726.20. Following the transaction, the insider now directly owns 295,433 shares of the company’s stock, valued at $1,979,401.10. The trade was a 1.53 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel David Aaron Lehman sold 5,765 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $6.69, for a total value of $38,567.85. Following the sale, the general counsel now directly owns 203,348 shares of the company’s stock, valued at $1,360,398.12. This represents a 2.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 70,351 shares of company stock worth $494,094 over the last three months. Company insiders own 5.70% of the company’s stock.

Institutional Trading of Pulmonx

Large investors have recently made changes to their positions in the business. Squarepoint Ops LLC raised its holdings in shares of Pulmonx by 261.2% in the second quarter. Squarepoint Ops LLC now owns 144,409 shares of the company’s stock valued at $916,000 after buying an additional 104,432 shares during the last quarter. Sei Investments Co. raised its stake in shares of Pulmonx by 2.5% in the first quarter. Sei Investments Co. now owns 72,626 shares of the company’s stock worth $673,000 after acquiring an additional 1,800 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of Pulmonx during the third quarter worth approximately $102,000. XTX Topco Ltd bought a new stake in shares of Pulmonx during the second quarter valued at approximately $222,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in shares of Pulmonx by 7.0% in the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,059,018 shares of the company’s stock valued at $6,714,000 after purchasing an additional 69,595 shares in the last quarter. Institutional investors own 91.04% of the company’s stock.

Pulmonx Stock Down 2.5 %

LUNG opened at $6.30 on Friday. Pulmonx has a 1-year low of $5.46 and a 1-year high of $14.84. The business has a 50 day moving average of $6.96 and a 200-day moving average of $7.08. The stock has a market capitalization of $248.79 million, a price-to-earnings ratio of -4.29 and a beta of 0.68. The company has a current ratio of 7.70, a quick ratio of 6.77 and a debt-to-equity ratio of 0.40.

Pulmonx (NASDAQ:LUNG) last issued its quarterly earnings results on Wednesday, October 30th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.07. Pulmonx had a negative net margin of 72.01% and a negative return on equity of 53.88%. The firm had revenue of $20.39 million during the quarter, compared to the consensus estimate of $20.39 million. During the same period in the prior year, the firm earned ($0.39) EPS. As a group, sell-side analysts anticipate that Pulmonx will post -1.53 earnings per share for the current year.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.